Study of uptake, break down and elimination of an investigational drug in healthy volunteers - MB
Study identifier:D3690C00017
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers with Different CYP2D6 Genotype
Medical condition
Alzheimer's disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3480
Sex
Male
Actual Enrollment
9
Study type
Interventional
Age
35 Years - 65 Years
Date
Study Start Date: 01 Oct 2008
Primary Completion Date: 01 Oct 2009
Study Completion Date: 01 Oct 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD3480 iv Single iv infusion AZD3480 | Drug: AZD3480 Iv single dose, 4-hour infusion of 25 mg |
| Experimental: Oral [14C] AZD3480 Single oral dose [14C]AZD3480 | Drug: AZD3480 Oral solution single dose of 50 mg |
Contacts
Investigators
Principal Investigator
Björn Paulsson
AstraZeneca Södertälje, Sweden
